Floatz logo

Chloroquine

Sickle Cell Disease

London School of Hygiene and Tropical MedicineSmall moleculePhase 2/3Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
65/ 100

Competitive context

135 Active assets in the Sickle Cell Disease cohort.

Asset / SponsorPhaseRating
Glutamine
Ain Shams University
Phase 4BBB
Hydroxyurea
St. Jude Children's Research Hospital
Phase 4BB
Crizanlizumab
Novartis Pharmaceuticals
Phase 4BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 4BB
MAGNESIUM METALLICUM
Medical College of Wisconsin
Phase 3BB

View all 50 →

Same molecule, other indications

Chloroquine is also rated in:

glioblastomaDormant
B
Indicative ·
58 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
CCC
Indicative ·
52 / 100
View asset →
hypertensive disorderDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →